热门资讯> 正文
学者洛克被列入韦德布什的最佳创意名单
2026-09-26 01:17
- Scholar Rock Holding(SRRK) 0
- Invesco Strategic Emerging Markets ETF(ISEM) 0
- iShares收益最佳化债券ETF(BYLD) 0
- Outperform-rated Scholar Rock Holding Corp. (SRRK) has been added to Wedbush's Best Ideas List as it is "uniquely positioned to deliver a durable, de-risked commercial ramp in the neuromuscular space."
- The firm has a $70 price target (44% upside based on Sept. 24 close).
- Analyst David Nierengarten said that the company is being helped by Isembyld's (apitegromab) first-in-class launch for spinal muscular atrophy and its myostatin pipeline.
- He noted that a recent pullback in shares, likely due to a US FDA post-marketing safety commitment for Isembyld and lower-than-expected pricing, provides an attractive entry point.
- Nierengarten sees Isembyld US revenue of ~$5M this year, rising to $140M in 2027, $349M in 2028, and $634M in 2029. Worldwide revenue could surpass $2B by 2031.
- He added that studies examining Isembyld in SMA patients under the age of two years old and for facioscapulohumeral muscular dystrophy could provide additional upside.
More on Scholar Rock
- Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
- Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
- Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
- Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
推荐文章
一周财经日历 | 事关加息进程！美国9月CPI、PPI数据下周来袭；Q3财报季打响，银行股、台积电等放榜在即！
美股前瞻 | 龙头订单排到2029年！光通信股盘前集体爆发，Lumentum劲升逾6%；新产品销量遇冷，苹果盘前走弱；瑞银喊话黄金“回调即买入”
丘盛一筹 | 别被盘面骗了！OpenAI收入谣言作祟，AI板块、半导体纯属错杀?
华盛早报 | OpenAI营收被爆200亿美元预期差！AI板块遭重创；特朗普中期选举前对伊挂“免战牌”，SpaceX收购低频段频谱，美运营商夜盘暴跌
10月9日外盘头条：特朗普称中期选举前不会攻击伊朗 苹果将举行智能家居新品发布会 OpenAI年化营收500亿美元
英伟达、甲骨文、CoreWeave及其他AI股票因OpenAI营收报告下跌
美股前瞻 | 特朗普威胁中期选举前再袭伊！国际油价大升4%，三大期指齐跌；投行喊出美光3000美元目标价；华尔街知名多头公布五大首选股
资金复盘 | 北水加仓腾讯逾24亿港元！友邦保险、小米集团-W同获抢筹
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
